Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Accelerating innovations in systemic therapy for pleural mesothelioma

Malignant pleural mesothelioma is a challenging disease with few approved treatments. Rapidly expanding insights into the pathogenesis of this cancer and clinical trials are now suggesting a variety of targeted and immune-oncology agents with the potential to address unmet clinical needs.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Timeline of key developments in systemic therapy for patients with MPM.

References

  1. Nicholson, A. G. et al. J. Thorac. Oncol. 15, 29–49 (2020).

    Article  CAS  Google Scholar 

  2. Baas, P. et al. Lancet 397, 375–386 (2021).

    Article  CAS  Google Scholar 

  3. Szlosarek, P. W. et al. JAMA Oncol. 3, 58–66 (2017).

    Article  Google Scholar 

  4. Hmeljak, J. et al. Cancer Discov. 8, 1548–1565 (2018).

    Article  CAS  Google Scholar 

  5. Zauderer, M. G. et al. Lancet Oncol. 23, 758–767 (2022).

    Article  CAS  Google Scholar 

  6. Ding, H. et al. Cell Rep. 27, 3331–3344.e3336 (2019).

  7. Fennell, D. A. et al. Lancet Oncol. 23, 374–381 (2022).

    Article  CAS  Google Scholar 

  8. Kryukov, G. V. et al. Science 351, 1214–1218 (2016).

    Article  CAS  Google Scholar 

  9. Wu, J. et al. Nature 572, 402–406 (2019).

    Article  CAS  Google Scholar 

  10. Fennell, D. A. et al. Lancet Respir. Med. 9, 593–600 (2021).

    Article  CAS  Google Scholar 

  11. Fennell, D. A. et al. Lancet Oncol. 22, 1530–1540 (2021).

    Article  CAS  Google Scholar 

  12. Forde, P. M. et al. Nat. Med. 27, 1910–1920 (2021).

    Article  CAS  Google Scholar 

  13. Adusumilli, P. S. et al. Cancer Discov. 11, 2748–2763 (2021).

    Article  CAS  Google Scholar 

  14. Pinto, C. et al. Lancet Oncol. 22, 1438–1447 (2021).

    Article  CAS  Google Scholar 

  15. Fennell, D. A. et al. J. Clin. Oncol. 39, 8507 (2021).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dean A. Fennell.

Ethics declarations

Competing interests

D.A.F. has received research grants from Astex Therapeutics, Bayer, Bristol Myers Squibb, Boehringer Ingelheim and Pierre Fabre; fees from Aldeyra, Atara Biotherapeutics, Bristol Myers Squibb, Cambridge Clinical Laboratories, Inventiva and Targovax; and non-financial support from Clovis, Eli Lilly, Roche, Bergen Bio, Bristol Myers Squibb, MSD and Pierre Fabre.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fennell, D.A., Bzura, A. Accelerating innovations in systemic therapy for pleural mesothelioma. Nat Cancer 3, 902–904 (2022). https://doi.org/10.1038/s43018-022-00419-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00419-5

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer